• Facebook
  • Twitter
  • Youtube
  • Instagram
  • LinkedIn
  • Rss
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • The 1986 Club
    • Our Team
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • State of Survivorship Survey
      • 2022 Survey
      • 2021 Survey
      • 2020 Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Advocate Engagement Opportunities
    • Survivorship Champions
    • Subscribe to NCCS Updates
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State-Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Cancer Rehabilitation
    • Integrative Oncology
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Telehealth
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • 2022 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Fall 2022 CPR
      • Spring 2022 CPR
      • Fall 2021 CPR
      • Spring 2021 CPR
      • Fall 2020 CPR
      • Spring 2020 CPR
    • Cancer Policy and Advocacy Team (CPAT) Virtual Symposium 2022
    • 2022 State of Survivorship Survey Results
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Your generous year-end donation will be matched $1 for $1    DONATE

Bateman House Thumb

Guest Post: Are Right to Try Laws a Good Idea?

December 10, 2014/in Cancer News, Cancer Policy Blog NCCS News
bateman-house_alison_1338

Guest Post by Alison Bateman-House, PhD, MPH, MA New York University Langone Medical Center

Are right to try laws a good idea?  During 2014, they began appearing throughout the country, first in Colorado, then in Missouri and Louisiana, and, just recently, in Michigan and Arizona.  Similar legislation is now or will soon be under consideration in New Jersey, Delaware, Nevada, Texas, and Wyoming.

At first glance, these laws may seem worth enacting.  They promise terminally ill patients the ability to try experimental drugs, devices, or biological products (for example, stem cell-based treatments) in their quest to save or extend their lives.  These potential therapies are still in development and have not completed the testing that the Food and Drug Administration (FDA) requires for a treatment to be approved for sale or use in the United States.

The problem is that these laws do not deliver on their promises and some of the laws may harm the very patients that those backing the right to try concept want to help.  How can this be?  The answer lies in what the laws actually say.  From state to state, the laws are quite similar, showing their direct derivation from a model bill put out by the Goldwater Institute, a conservative think tank based in Arizona.  According to this model bill,

A manufacturer of an investigational drug…may make available and an eligible patient may request the manufacturer’s investigational drug…under this act.  This act does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.

So, patients may ask, and companies may provide – if they want.  This means that the right to try is not really a “right” at all, as nobody is obligated to give the patient anything.  It gets worse.  Elsewhere in the model bill it says, “A manufacturer may…[R]equire an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.”  Not only may the company charge the patient, but insurers do not have to cover these costs.

How does this differ from the situation facing the terminally ill today?  Not at all.  Patients do not need a new law in order to be able to make “compassionate use” requests of experimental products.  Ironically, the new laws – which pertain only to dying patients – are more restrictive than the current system, in which patients seek compassionate use access hoping to stave off blindness, paralysis, or any number of other serious but not fatal problems.

The current system is far from perfect.  As compassionate use requests are normally channeled through doctors, patients who do not have access to high quality healthcare providers may never be informed of the possibility of compassionate use.  Right to try laws offer no solution to this problem, stating only that doctors will not get in trouble for recommending or being involved in the use of an investigational product.  (This is a red herring: I know of no such cases.  If a doctor gets in trouble, there was something else going on, such as a fraudulent claim of efficacy for the experimental product.)

If they cannot find a doctor to channel their requests, patients can make their own compassionate use requests, provided they find some way – on the phone, on social media, through the local news media – to contact the company.  Again, this poses problems: for example, not everyone is able to navigate the media or the internet successfully.  But again, right to try laws do not help fix this situation.

The key difference between the current situation and the situation as it would be under a right to try law is that suddenly medical products that have gone through Phase I testing (safety testing only) would be considered quasi-therapeutic agents, even though they have not be tested for efficacy.  And while terminally ill patients would have to sign a form testifying that they understand the potential treatment is experimental and has not been shown to work in humans, several of the laws state that “eligibility for hospice care may be withdrawn if the patient begins curative treatment with the investigational drug.” Colorado’s law goes even further, stating that patients in such cases might lose in-home healthcare or certain types of insurance coverage.

The “right to try” is an appealing slogan, but it is hollow, offering only false hope.  Furthermore, it is fundamentally wrong to penalize dying patients simply because they want to try an experimental treatment.  The false hope these laws generate, coupled with the fact that hospice or other kinds of care may be withdrawn from those who need it, makes it clear that the right to try concept does not help the dying and may, in fact, leave them worse off.

Alison Bateman-House is a Rudin Post-Doctoral Fellow in the New York University Department of Population Health, where she serves as the deputy director of the NYU Working Group on Conscientious Objection.  She holds a doctoral degree from Columbia University’s Department of Sociomedical Sciences, and she also has graduate degrees in public health and bioethics. 

The views & opinions expressed in any guest post featured on our site are those of the guest author and do not necessarily reflect the opinions & views of the National Coalition for Cancer Survivorship. Read our blog and comment policies here.

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
https://canceradvocacy.org/wp-content/uploads/2014/12/Bateman-House-Thumb.png 321 699 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2014-12-10 10:29:582014-12-10 10:29:58Guest Post: Are Right to Try Laws a Good Idea?

Latest News

Webinar – Survivorship at Atrium Health Wake Forest Baptist Comprehensive Cancer Center: Creating a Practical Workflow

May 12, 2023
The National Coalition for Cancer Survivorship (NCCS) hosted a Survivorship Champions webinar about survivorship care implementation,…
Read more
https://canceradvocacy.org/wp-content/uploads/Atrium-Health-Wake-Forest-Baptist-update-POST.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-05-12 12:42:192023-05-12 21:48:11Webinar – Survivorship at Atrium Health Wake Forest Baptist Comprehensive Cancer Center: Creating a Practical Workflow

Sandra Finestone, PsyD: Be Bold and Don’t Hesitate – A 30-year Survivor’s Advice on Advocacy

May 8, 2023
Advocate Spotlight: Sandra Finestone, PsyD A cancer diagnosis can be overwhelming and life-changing, but for Sandra Finestone, it…
Read more
https://canceradvocacy.org/wp-content/uploads/Sandra-Finestone-Advocate-Spotlight-Blog-Banner.png 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-05-08 13:42:472023-05-11 10:49:23Sandra Finestone, PsyD: Be Bold and Don’t Hesitate – A 30-year Survivor’s Advice on Advocacy

Accessing COVID-19 Resources After the Public Health Emergency Ends

May 4, 2023
The COVID-19 public health emergency (PHE), which has been in effect since early 2020, will end on May 11, 2023. The federal government…
Read more
https://canceradvocacy.org/wp-content/uploads/Blog-Webpage-Banner-3.png 600 1200 Kara Kenan https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png Kara Kenan2023-05-04 17:52:452023-05-04 17:52:45Accessing COVID-19 Resources After the Public Health Emergency Ends

Take Action

Make An Impact

We are relentless in improving the quality of care and life after a cancer diagnosis. Your support makes all the difference right now.

Make a Gift »

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • This field is for validation purposes and should be left unchanged.

  • About
    • Our Mission
    • Our History
    • The 1986 Club
    • Our Team
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • State of Survivorship Survey
      • 2022 Survey
      • 2021 Survey
      • 2020 Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Advocate Engagement Opportunities
    • Survivorship Champions
    • Subscribe to NCCS Updates
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State-Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Cancer Rehabilitation
    • Integrative Oncology
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Telehealth
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • 2022 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Fall 2022 CPR
      • Spring 2022 CPR
      • Fall 2021 CPR
      • Spring 2021 CPR
      • Fall 2020 CPR
      • Spring 2020 CPR
    • Cancer Policy and Advocacy Team (CPAT) Virtual Symposium 2022
    • 2022 State of Survivorship Survey Results
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2023 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

We’re Going Digital: Last Week to Order Cancer Survival Toolbox – Blood...Blood Cancer ProgramsNCCS Starburst ThumbnailWCOE: Cost of Cancer Care, Adopting a Shorter Course of Treatment for Some Breast...
Scroll to top
Download the Survey Report

"*" indicates required fields

Fill out the form below, and we’ll send the survey report, detailed presentation, and infographic to your email.
Name*
I am a...*
Select any/all that apply.
Consent*
By downloading the survey materials, you will receive updates and information from NCCS via email, which you may unsubscribe from at any time. Your information will never be sold to any third parties.
This field is for validation purposes and should be left unchanged.

Get Updates From NCCS

Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.

  • This field is for validation purposes and should be left unchanged.

Connect With Us

Twitter     Facebook     Instagram     LinkedIn     YouTube

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute